At the Goldman Sachs 47th Annual Global Healthcare Conference held on June 8, 2026, Tandem Diabetes Care, Inc. showcased significant developments, particularly the recent CE Mark approval for its pregnancy indication. John Sheridan, the President and CEO, noted that this approval is vital for women with type 1 diabetes who are considering pregnancy. The company conducted a successful symposium, presenting data to a large group of medical professionals, which was positively received. Sheridan highlighted the importance of targeting women in child-bearing years, as the product is designed for use before and during pregnancy. The conference provided an opportunity to reflect on key market themes and customer feedback, reinforcing Tandem's commitment to addressing the needs of this specific population. Overall, the event was deemed successful, with strong interest in Tandem's innovations and their potential impact on diabetes management during pregnancy.